Enterome products

OncoMimicsTM vaccines are a specific combination of bacterial peptides, derived from bacteria present in the gut microbiome, that closely mimic either overexpressed tumor-associated antigens (TAAs) or lineage-specific markers in solid and liquid tumors, respectively.

New generation of oral bioactives to treat inflammatory and autoimmune diseases. EndoMimicsTM are first-in-class orally available bioactives drugs based on proteins secreted by the gut bacteria that act like human hormones or cytokines. Enterome expects partnering to play a central in generating value from its EndoMimics pipeline.

Sibofimloc is a first-in-class, orally administered small molecule that is specifically designed to reduce the inflammatory cascade underlying Crohn’s disease and remain gut-restricted, to minimize absorption into the bloodstream.

EO2463 comprises OncoMimics that are highly expressed on B-cell malignancies.

EO2401 is an innovative, off-the-shelf immunotherapy discovered by Enterome.

EO2463 is an innovative, off-the-shelf therapeutic cancer vaccine discovered by Enterome. EO2463 combines four OncoMimics peptides (bacterial peptides) of B lymphocyte-specific lineage markers. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes enriched in indolent non-Hodgkin lymphoma (iNHL). EO2463 is being evaluated in a Phase 1/2 clinical trial as monotherapy and in combination with standard-of-care lenalidomide and/or rituximab for the treatment of iNHL (SIDNEY study, EONHL1-20).